1015073-42-3

Basic information

• Product Name: PSI7409
• Synonyms: PSI 7409;PSI7409;PSI-7409
• CAS NO: 1015073-42-3
• Molecular Weight: 0
• Mol File: 1015073-42-3.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: PSI7409(CAS DataBase Reference)
• NIST Chemistry Reference: PSI7409(1015073-42-3)
• EPA Substance Registry System: PSI7409(1015073-42-3)

Safety Data

• Hazardous Substances Data: 1015073-42-3(Hazardous Substances Data)

Usage

General Description

PSI7409 is a chemical compound that belongs to the class of phosphodiesterase inhibitors. It has been found to inhibit the activity of various phosphodiesterase enzymes, particularly PDE4, which are involved in the regulation of intracellular levels of cyclic nucleotides such as cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). By inhibiting these enzymes, PSI7409 has been shown to increase levels of cAMP and cGMP in cells, leading to a variety of pharmacological effects including anti-inflammatory, bronchodilator, and anti-tumor activities. Research on PSI7409 is ongoing, with potential applications in the treatment of inflammatory diseases such as asthma and chronic obstructive pulmonary disease (COPD), as well as cancer.

Upstream product

• 114262-45-2 1-<2-C-methyl-3,5-O-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)-β-D-arabino-pentofuranosyl>-uracil 
• 114262-49-6 1-(2'-C-methyl-β-D-arabinofuranosyl)uracil 
• 944476-44-2 ((2R,3R,4S,5R)-3-(benzoyloxy)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-hydroxy-4-methyltetrahydrofuran-2-yl)methyl benzoate 
• 863329-65-1 (2‘R)-2‘-deoxy-2’-fluoro-2-methyluridine-3’,5’-dibenzoate 
• 58-96-8 uridine 
• 69304-38-7 3',5'-(1,1,3,3-tetraisopropyldisiloxane-1,3-diyl)uridine 
• 84828-97-7 1-((6aR,8R,9aR)-2,2,4,4-tetraisopropyl-9-oxotetrahydro-6H-furo[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl)pyrimidine-2,4(1H,3H)-dione 
• 1015073-43-4 GS-606965 
• 863329-66-2 2'-deoxy-2'-fluoro-2'-methyluridine 

Relevant articles and documents

Synthesis and Anti-HCV Activities of 4′-Fluoro-2′-Substituted Uridine Triphosphates and Nucleotide Prodrugs: Discovery of 4′-Fluoro-2′- C-methyluridine 5′-Phosphoramidate Prodrug (AL-335) for the Treatment of Hepatitis C Infection

We report the synthesis and biological evaluation of a series of 4′-fluoro-2′-C-substituted uridines. Triphosphates of the uridine analogues exhibited a potent inhibition of hepatitis C virus (HCV) NS5B polymerase with IC50 values as low as 27 nM. In an HCV subgenomic replicon assay, the phosphoramidate prodrugs of these uridine analogues demonstrated a very potent activity with EC50 values as low as 20 nM. A lead compound AL-335 (53) demonstrated high levels of the nucleoside triphosphate in vitro in primary human hepatocytes and Huh-7 cells as well as in dog liver following a single oral dose. Compound 53 was selected for the clinical development where it showed promising results in phase 1 and 2 trials.